News

Untreated IPF Linked to 50% Mortality Rate at 3 Years

If left untreated by anti-fibrotic medications, idiopathic pulmonary fibrosis (IPF) has a 50% mortality rate after three years, according to a recent observational study using real-world data. This is compared with a 26–31% mortality rate among IPF patients taking available anti-fibrotics, such as Esbriet (pirfenidone) and Ofev…

Ofev, Esbriet Found to Significantly Reduce Risk of Death in IPF

Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action — “offers protection” and can slow lung function decline in people with pulmonary fibrosis (PF), according to a new analysis. Moreover, the results showed that these medications can significantly reduce…

Top 10 Pulmonary Fibrosis Stories of 2021

Pulmonary Fibrosis News brought you daily coverage throughout 2021 of the latest scientific findings, treatment developments, and clinical trials related to pulmonary fibrosis (PF). As a reminder of what mattered most to you during the past year, here are the top 10 most-read articles of 2021, with a brief…

University of Calgary Creating Survey to Help Pinpoint Risks of PF

The University of Calgary is developing a clinical tool to help identify the environmental and occupational risks of pulmonary fibrosis (PF), an undertaking that could lead to a deeper understanding of how the disease takes hold and aid in developing treatments. During the 18-month project, supported by the Three…

Eucalyptus Compound Found to Reduce Lung Damage in PF Sheep

Pinocembrin, a compound isolated from eucalyptus trees, significantly reduced the signs and symptoms of lung damage in a sheep model of pulmonary fibrosis (PF), a study demonstrated. “We found that pinocembrin improved lung function, attenuated [eased the effect of] lung inflammation, and decreased overall pathology scores compared to damaged…

AstraZeneca, BenevolentAI Identify New Treatment Target

AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF) to its portfolio, which was uncovered using BenevolentAI’s artificial intelligence-driven medication discovery platform. “The cause of IPF is largely unknown and the exact mechanisms involved in the progression of IPF remain elusive,” Anne Phelan, PhD, chief scientific…